In vivo, the BsAb TAVO101 × IL4R-dupi reduced all hallmark features of allergic disease, including IgE production, IL-5 and CCL17 levels, eosinophilic infiltration, and mucus hypersecretion. This evidence concerns the gene CCL17 and allergic disease.